Research advances of myeloid neoplasmas in 2015

doi:10.3969/j.issn.1004-583X.2016.02.005

Abstract

Abstract: The research advances of myeloid neoplasms in 2015 will be introduced,such as new molecularly targeted therapies for acute myeloid leukemia(AML),reclassifying myelodysplastic syndromes(MDS),precise diagnosis and risk assessment of MDS,novel therapeutic approaches of MDS,refining risk stratification and treatment strategy in primary myelofibrosis.

Key words: leukemia, myeloid, myelodysplastic syndromes, primary myelofibrosis , molecularly targeted therapy

CLC Number:

R551.3

Ren Jinhai, Guo Xiaonan, Guo Xiaoling, Cai Shengxin. Research advances of myeloid neoplasmas in 2015[J]. Clinical Focus, 2016, 31(2): 151-155.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.02.005

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I2/151

References

[1] Burnett A,Wetzler M,Lowenberg B.Therapeutic advances in acute myeloid leukemia[J].J Clin Oncol,2011,29(5):487-494.
[2] Dombret H,Seymcur JF,Butrym A,et al.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with>30% blasts[J].Blood,2015,126(3):291-299.
[3] Levis M.FLT3 mutations in acute myeloid leukemia:what is the best approach in 2013[J] Hematology AM Soc Hematol Educ Program,2013,2013(1):220-226.
[4] Cortes JE,Kantarjian H,Foran JM,et al.Phase Ⅰ study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status[J].J Clin Oncol,2013,31(29):3681-3687.
[5] Levis MJ,Perl AE,Dombret H,et al.Final results of a phase 2 open-label,monotherapy efficacy and safety study of quizartinib(AC220) in patients with FLT3-ITD positive or negtive relapsed/refractory acute myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantation[C].ASH Annual Meeting Abstracts,2012,120(21):Abstract 673.
[6] Cortes JE,Perl AE,Dombret H,et al. Final results of a phase 2 open-label,monotherapy efficacy and safety study of quizartinib(AC220) in patients≥60 years of age with FLT3-ITD positive or negtive relapsed/refractory acute myeloid leukemia[C].ASH Annual Meeting Abstracts,2012,120(21):Abstract 48.
[7] Schiller GJ,Tallman MS,Goldberg SL,et al. Final results of a randomized phase 2 study showing the clinical benefit of quizartinib(AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia[J].J Clin Oncol,2014,32:5s(Suppl).Abstract 7100.
[8] Randhawa JK,Kantarjian HM,Borthakur G,et al.Results of phase Ⅱ study of Crenolanib in relapsed/refractory acute myeloid leukemia patients with activating FLT3 mutations[J].Blood,2014,124(21):389.
[9] Levis MJ,Pearl AE,Altman JK,et al.Results of a first-in-human,phase Ⅰ/Ⅱ trial of ASP-2215,a selective,potent inhibitor of FLT3/AXL in patients with relapsed or refractory(R/R) acute myeloid leukemia(AML)[J]. J Clin Oncol,2015,33(Suppl).Abstract 7003.
[10] Lu C,Ward PS,Kapoor GS,et al.IDH mutation impairs histone demethylation and results in a block to cell differentiation[J].Nature,2012,483(7390):474-478.
[11] Chan SM,Thomas D,Corces-Zimmerman MR,et al.Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia[J].Nat Med,2015,21(2):178-184.
[12] Della Porta MG,Thavaglino E,Boveri E,et al.Minimal morphological criteria for defining bone marrow dysplasia:a basis for cinical implementation of WHO classification of myelodysplastic syndromes[J].Leukemia,2015,29(1):66-75.
[13] Maassen A,Strupp C,Giagounidis A,et al.Validation and proposals for a refinement of the WHO 2008 classification of myelodysplastic syndromes without excess of blasts[J].Leuk Res,2013,37(1):64-70.
[14] Valcarcel D,Adema V,Sole F,et al.Complex,not monosomal,karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome[J].J Clin Oncol,2013,31(7):916-922.
[15] Gerstung M,Pellagatti A,Malcovati L,et al.Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes[J].Nat Commun,2015,6:5901.
[16] Germing U,Lauseker M,Hildebrandt B,et al.Survival,prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q);a multicenter study[J].Leukemia,2012,26(6):1286-1292.
[17] Grossmann V,Bacher U,Haferlach C,et al.Acute erythroid leukemia(AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics[J].Leukemia,2013,27(9):1940-1943.
[18] Zhang MY,Churpek JE,Keel SB,et al.Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy[J].Nat Genet,2015,47(2):180-185.
[19] West AH,Godley LA,Churpek JE.Familial myelodysplastic syndrome/acute leukemia syndromes:a review and utility for translational investigations[J].Ann N Y Acad Sci,2014,1310:111-118.
[20] Bejar R,Stevenson K,Abdel-Wahab O,et al.Clinical effect of point mutations in myelodysplastic syndromes[J].N Engl J Med,2011,364(26):2496-2506.
[21] Papaemmanuil E,Gerstung M,Malcovati L,et al.Clinical and biological implications of driver mutations in myelodysplastic syndromes[J].Blood,2013,122(22):3616-3627;quiz3699.
[22] Haferlach T,Nagata Y,Grossmann V,et al.Landscape of genetic lessions in 944 patients with myelodysplastic syndromes[J].Leukemia,2014,28(2):241-247.
[23] Bejar R,Stevenson KE,Caughey B,et al.Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoitic stem cell transplantation[J].J Clin Oncol,2014,32(25):2691-2698.
[24] Traina F,Visconte V,Elson P,et al.Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms[J].Leukemia,2014,28(1):78-87.
[25] Bejar R,Lord A,Stevenson K,et al.TET2 mutations predict response to hypomethylating agents in myelodyplastic syndrome patients[J].Blood,2014,124(17):2705-2712.
[26] Bally C, Ades L,Renneville A,et al.Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine[J].Leuk Res,2014,38(7):751-755.
[27] Haferlach T,Nagata Y,Grossmann V,et al.Landscape of genetic lesions in 944 patients with myelodysplastic syndromes[J].Leukemia,2014,28(2):241-247.
[28] Jabbour EJ,Garcia-Manero G,Strati P,et al.Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure:a report on behalf of the MDS Clinical Research Consortium[J].Cancer,2015,121(6):876-882.
[29] Prebet T,Gore SD,Esterni B,et al.Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure[J].J Clin Oncol,2011,29(24):3322-3327.
[30] Sekeres MA,Tiu RV,Komrokji R,et al.Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes[J].Blood,2012,120(25):4945-4951.
[31] Sekeres MA,Giagounidis A,Kantarjian H,et al.Development and validation of a model to predict platelet response to romiplostim in patients with low-risk myelodysplastic syndromes[J].Br J Haematol,2014,167(3):337-345.
[32] Platzbecker H,Germing U,Giagounidis A,et al.ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk myelodysplastic syndromes(MDS):preliminary results from a phase 2 study[J].Blood,2014,124:411.
[33] Silverman LR,Greenberg P,Raza A,et al.Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy[J].Hematol Oncol,2015,33(2):57-66.
[34] Ortmann CA,Kent DG,Nangalia J,et al.Effect of mutation order on myeloproliferative neoplasms[J].N Engl J Med,2015,372:601-612.
[35] Vannucchi A,Guglielmelli P,Rotunno G,et al.Mutation-enhanced international prognostic scoring system(MIPSS) for primary myelofibrosis:an AGIMM & IWG-MRT project[J].Blood,2014,124(21):405.
[36] Tefferi A,Guglielmelli P,Finke C,et al.Integration of mutations and karyotype towards a genetics-based prognostic scoring system(GPSS) for primary myelofibrosis[J].Blood,2014,124(21):406.